CUSP06/AMT-707, a new CDH6-targeting antibody-drug conjugate, demonstrates potent antitumor activity in preclinical models

被引：0
|
作者：
Lu, Wei
Shi, Jing
Liu, Shu-Hui
Covino, Nicole
Meng, Xun
Slosberg, Eric D.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-6320
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6320
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma
    Brignole, Chiara
    Calarco, Enzo
    Bensa, Veronica
    Giusto, Elena
    Perri, Patrizia
    Ciampi, Eleonora
    Corrias, Maria Valeria
    Astigiano, Simonetta
    Cilli, Michele
    Loo, Derik
    Bonvini, Ezio
    Pastorino, Fabio
    Ponzoni, Mirco
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (09)
  • [22] IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML
    Kovtun, Yelena
    Noordhuis, Paul
    Whiteman, Kathleen R.
    Watkins, Krystal
    Jones, Gregory E.
    Harvey, Lauren
    Lai, Katharine C.
    Portwood, Scott
    Adams, Sharlene
    Sloss, Callum M.
    Schuurhuis, Gerrit Jan
    Ossenkoppele, Gert
    Wang, Eunice S.
    Pinkas, Jan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (06) : 1271 - 1279
  • [23] Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer
    Kanda, Mizuki
    Serada, Satoshi
    Hiramatsu, Kosuke
    Funauchi, Masashi
    Obata, Kengo
    Nakagawa, Satoshi
    Ohkawara, Tomoharu
    Murata, Okinori
    Fujimoto, Minoru
    Chiwaki, Fumiko
    Sasaki, Hiroki
    Ueda, Yutaka
    Kimura, Tadashi
    Naka, Tetsuji
    NEOPLASIA, 2023, 35
  • [24] Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
    Challita-Eid, Pia M.
    Satpayev, Daulet
    Yang, Peng
    An, Zili
    Morrison, Karen
    Shostak, Yuriy
    Raitano, Arthur
    Nadell, Rossana
    Liu, Wendy
    Lortie, Dawn Ratay
    Capo, Linnette
    Verlinsky, Alla
    Leavitt, Monica
    Malik, Faisal
    Avina, Hector
    Guevara, Claudia I.
    Dinh, Nick
    Karki, Sher
    Anand, Banmeet S.
    Pereira, Daniel S.
    Joseph, Ingrid B. J.
    Donate, Fernando
    Morrison, Kendall
    Stover, David R.
    CANCER RESEARCH, 2016, 76 (10) : 3003 - 3013
  • [25] A novel dual drug antibody-drug conjugate targeting hTrop2 has synergetic antitumor activity in solid tumor models
    Zhu, Jie
    Zhao, Xiaobei
    Li, Eileen
    Xu, Hong
    Nie, Lei
    Chen, Gang
    Wang, Haibing
    CANCER RESEARCH, 2024, 84 (06)
  • [26] OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models
    Li, Wan-Fen
    Chiang, Ming-Feng
    Weng, Hao-Cheng
    Yang, Jhih-Jie
    Wu, Hsin-Shan
    Wu, Szu-Yu
    Chen, Yu-Jung
    Lu, Chi-Huan
    Tu, Jyy-Shiuan
    Hsu, Ren-Yu
    Shia, Chi-Sheng
    Huang, Teng-Yi
    Lai, Ming-Tain
    MOLECULAR CANCER THERAPEUTICS, 2025, 24 (02) : 163 - 175
  • [27] Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models
    Whiteman, Kathleen R.
    Johnson, Holly A.
    Mayo, Michele F.
    Audette, Charlene A.
    Carrigan, Christina N.
    LaBelle, Alyssa
    Zukerberg, Lawrence
    Lambert, John M.
    Lutz, Robert J.
    MABS, 2014, 6 (02) : 556 - 566
  • [28] FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models
    Guo, Qingsong
    Gao, Bei
    Song, Ruiwen
    Li, Weinan
    Zhu, Shulei
    Xie, Qian
    Lou, Sensen
    Wang, Lei
    Shen, Jiafei
    Zhao, Teng
    Zhang, Yifan
    Wu, Jinsong
    Lu, Wei
    Yang, Tong
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (10) : 1367 - 1377
  • [29] Disitamab vedotin, a clinical stage HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical breast cancer models
    Willis, Kelsi
    Hein, Renee
    Snead, Katie
    Thurman, Robert
    Kulukian, Anita
    CANCER RESEARCH, 2024, 84 (09)
  • [30] SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
    Mazahreh, Rebecca
    Mason, Marsha L.
    Gosink, John J.
    Olson, Devra J.
    Thurman, Robert
    Hale, Christopher
    Westendorf, Lori
    Pires, Thomas A.
    Leiske, Christopher I.
    Carlson, Markus
    Nguyen, Liem T.
    Cochran, Julia H.
    Okeley, Nicole M.
    Yumul, Roma
    Jin, Steven
    Stone, Ivan J.
    Sahetya, Disha
    Nesterova, Albina
    Allred, Sean
    Hensley, Kelly M.
    Hu, Rachael
    Lawrence, Robert
    Lewis, Timothy S.
    Sandall, Sharsti
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (04) : 421 - 434
12345